These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

389 related articles for article (PubMed ID: 26565077)

  • 1. Effects of Dalfampridine Extended-release Tablets on 6-minute Walk Distance in Patients With Multiple Sclerosis: A Post Hoc Analysis of a Double-blind, Placebo-controlled Trial.
    Applebee A; Goodman AD; Mayadev AS; Bethoux F; Goldman MD; Klingler M; Blight AR; Carrazana EJ
    Clin Ther; 2015 Dec; 37(12):2780-7. PubMed ID: 26565077
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Estimation of the effect of dalfampridine-ER on health utility by mapping the MSWS-12 to the EQ-5D in multiple sclerosis patients.
    Limone BL; Sidovar MF; Coleman CI
    Health Qual Life Outcomes; 2013 Jun; 11():105. PubMed ID: 23799913
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dalfampridine extended release: in multiple sclerosis.
    Chwieduk CM; Keating GM
    CNS Drugs; 2010 Oct; 24(10):883-91. PubMed ID: 20839898
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term safety and efficacy of dalfampridine for walking impairment in patients with multiple sclerosis: Results of open-label extensions of two Phase 3 clinical trials.
    Goodman AD; Bethoux F; Brown TR; Schapiro RT; Cohen R; Marinucci LN; Henney HR; Blight AR;
    Mult Scler; 2015 Sep; 21(10):1322-31. PubMed ID: 25583832
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety, Tolerability, and Sensorimotor Effects of Extended-release Dalfampridine in Adults With Cerebral Palsy: A Pilot Study.
    Bethoux F; Fatemi A; Fowler E; Marciniak C; Mayadev A; Waksman J; Zackowski K; Suarez G; Blight AR; Rabinowicz AL; Carrazana E
    Clin Ther; 2017 Feb; 39(2):337-346. PubMed ID: 28131322
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of Dalfampridine Extended Release 5 and 10 mg in Multiple Sclerosis: A Randomized Controlled Trial.
    Yapundich R; Applebee A; Bethoux F; Goldman MD; Hutton GJ; Mass M; Pardo G; Klingler M; Henney HR; Blight AR; Carrazana EJ
    Int J MS Care; 2015; 17(3):138-45. PubMed ID: 26052259
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Assessment of Clinically Meaningful Improvements in Self-Reported Walking Ability in Participants with Multiple Sclerosis: Results from the Randomized, Double-Blind, Phase III ENHANCE Trial of Prolonged-Release Fampridine.
    Hobart J; Ziemssen T; Feys P; Linnebank M; Goodman AD; Farrell R; Hupperts R; Blight AR; Englishby V; McNeill M; Chang I; Lima G; Elkins J;
    CNS Drugs; 2019 Jan; 33(1):61-79. PubMed ID: 30535670
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Minimally important clinical difference of the Timed 25-Foot Walk Test: results from a randomized controlled trial in patients with multiple sclerosis.
    Coleman CI; Sobieraj DM; Marinucci LN
    Curr Med Res Opin; 2012 Jan; 28(1):49-56. PubMed ID: 22073939
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dalfampridine improves walking speed, walking endurance, and community participation in veterans with multiple sclerosis: a longitudinal cohort study.
    Cameron MH; Fitzpatrick M; Overs S; Murchison C; Manning J; Whitham R
    Mult Scler; 2014 May; 20(6):733-8. PubMed ID: 24099749
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Phase 3, double-blind, placebo-controlled efficacy and safety study of ADS-5102 (Amantadine) extended-release capsules in people with multiple sclerosis and walking impairment.
    Cohen JA; Cameron MH; Goldman MD; Goodman AD; Miller AE; Rollins A; Llorens L; Patni R; Elfont R; Johnson R
    Mult Scler; 2022 Apr; 28(5):817-830. PubMed ID: 34449295
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A phase 3 trial of extended release oral dalfampridine in multiple sclerosis.
    Goodman AD; Brown TR; Edwards KR; Krupp LB; Schapiro RT; Cohen R; Marinucci LN; Blight AR;
    Ann Neurol; 2010 Oct; 68(4):494-502. PubMed ID: 20976768
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A double-blind, randomized, controlled study of two dose strengths of dalfampridine extended release on walking deficits in ischemic stroke.
    Page SJ; Kasner SE; Bockbrader M; Goldstein M; Finklestein SP; Ning M; El-Feky WH; Wilson CA; Roberts H;
    Restor Neurol Neurosci; 2020; 38(4):301-309. PubMed ID: 32651338
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sustained-release oral fampridine in multiple sclerosis: a randomised, double-blind, controlled trial.
    Goodman AD; Brown TR; Krupp LB; Schapiro RT; Schwid SR; Cohen R; Marinucci LN; Blight AR;
    Lancet; 2009 Feb; 373(9665):732-8. PubMed ID: 19249634
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of dalfampridine on multi-dimensional aspects of gait and dexterity in multiple sclerosis among timed walk responders and non-responders.
    Lo AC; Ruiz JA; Koenig CM; Anderson BM; Olson KM; Triche EW
    J Neurol Sci; 2015 Sep; 356(1-2):77-82. PubMed ID: 26139339
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dose comparison trial of sustained-release fampridine in multiple sclerosis.
    Goodman AD; Brown TR; Cohen JA; Krupp LB; Schapiro R; Schwid SR; Cohen R; Marinucci LN; Blight AR;
    Neurology; 2008 Oct; 71(15):1134-41. PubMed ID: 18672472
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Patient perspectives and experience with dalfampridine treatment in multiple sclerosis-related walking impairment: the step together program.
    Crayton H; Sidovar M; Wulf S; Guo A
    Patient; 2015 Jun; 8(3):283-91. PubMed ID: 25475652
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Development of dalfampridine, a novel pharmacologic approach for treating walking impairment in multiple sclerosis.
    Blight AR; Henney HR; Cohen R
    Ann N Y Acad Sci; 2014 Nov; 1329():33-44. PubMed ID: 25154911
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sustained-release fampridine (4-aminopyridine) in multiple sclerosis: efficacy and impact on motor function.
    Rabadi MH; Kreymborg K; Vincent AS
    Drugs R D; 2013 Sep; 13(3):175-81. PubMed ID: 23873597
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Timed 25-foot walk: direct evidence that improving 20% or greater is clinically meaningful in MS.
    Hobart J; Blight AR; Goodman A; Lynn F; Putzki N
    Neurology; 2013 Apr; 80(16):1509-17. PubMed ID: 23535489
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prolonged-release fampridine and walking and balance in MS: randomised controlled MOBILE trial.
    Hupperts R; Lycke J; Short C; Gasperini C; McNeill M; Medori R; Tofil-Kaluza A; Hovenden M; Mehta LR; Elkins J
    Mult Scler; 2016 Feb; 22(2):212-21. PubMed ID: 25921050
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.